Investment Summary

Polaris Partners Invests In August Bioservices

On May 27, 2021, growth capital firm Polaris Partners invested in life science company August Bioservices

Investment Highlights
  • This is Polaris Partners’ 27th transaction in the Life Science sector.
  • This is Polaris Partners’ 65th transaction in the United States.
  • This is Polaris Partners’ 1st transaction in Tennessee.

Investment Summary
Date 2021-05-27
Target August Bioservices
Sector Life Science
Investor(s) Polaris Partners
Deal Type Venture

Target

August Bioservices

Nashville, Tennessee, United States
August Bioservices is a quality-driven CDMO that offers end-to-end drug research and development, cGMP laboratory services, and sterile fill/finish cGMP manufacturing to clients of all sizes and stages, from pre-clinical to commercial, all under one roof. August Bioservices was founded in 2017 and is based in Nashville, Tennessee.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Polaris Partners

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1996
PE ASSETS 5.0B USD
Size Large
Type Sector Agnostic
DESCRIPTION

Polaris Partners is primarily a seed, first round, and early stage venture capital investor in information technology and life science businesses. However, Polaris also focuses on private equity investments in established companies. In this area, Polaris targets high growth middle market companies in industries including technology, healthcare, digital media, consumer products and services, and business services. The firm's investments include minority growth equity investments, recapitalizations with liquidity, and leveraged buyouts. Polaris Partners was formed in 1996 and has offices in Seattle, Washington and Waltham, Massachusetts.

DEAL STATS #
Overall 72 of 87
Sector (Life Science) 27 of 39
Type (Venture) 44 of 57
State (Tennessee) 1 of 1
Country (United States) 65 of 78
Year (2021) 8 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-26 Engine Biosciences

Singapore, Singapore

Engine Biosciences is a drug discovery company using a proprietary AI and CRISPR-based platform to identify novel precision oncology targets. Engine Biosciences is based in Singapore.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-04 Cyclerion

Cambridge, Massachusetts, United States

Cyclerion is an independent company working at the forefront of CNS drug development. Cyclerion mission is to develop innovative medicines that improve brain function for patients in desperate need of new treatment options. Cyclerion was incorporated in 2018 and is based in Cambridge, Massachusetts.

Buy -
Mergr

Product

Company

Legal